Response Genetics

The firm was chapter 11 bankruptcy counsel to this company engaged in the research and development of clinical diagnostic cancer testing. The firm negotiated an asset-purchase agreement for the sale of substantially all of the company’s assets. The chapter 11 case was commenced, operations stabilized, and sale closed in the short span of sixty days.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.